Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Wan, Jinkai; Xing, Shenghui; Ding, Longfei; Wang, Yongheng; Gu, Cheng; Wu, Yanling; Rong, Bowen; Li, Cheng; Wang, Siqing; Chen, Kun; He, Chenxi; Zhu, Dandan; Yuan, Songhua; Qiu, Chengli; Zhao, Chen; Nie, Lei; Gao, Zhangzhao; Jiao, Jingyu; Zhang, Xiaoyan; Wang, Xiangxi; Ying, Tianlei; Wang, Haibin; Xie, Youhua; Lu, Yuele; Xu, Jianqing; Lan, Fei

doi:10.1016/j.celrep.2020.107918

Cited by 153 publications

(115 citation statements)

References 40 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Isolation of multiple human neutralizing monoclonal antibodies against SARS-CoV-2 has been reported (Cao et al, 2020; Chen et al, 2020; Chi et al, 2020; Hassan et al, 2020; Ju et al, 2020; Liu et al, 2020; Pinto et al, 2020; Robbiani et al, 2020; Rogers et al, 2020; Shi et al, 2020; Wan et al, 2020; Wang et al, 2020; Wu et al, 2020; Zeng et al, 2020; Zost et al, 2020). These antibodies can avoid the potential risks of human-anti-mouse antibody responses and other side effects (Hansel, Kropshofer, Singer, Mitchell, & George, 2010).…”

Section: Introductionmentioning

confidence: 99%

“…They will be appropriate for direct use in humans since they are humanized even if these monoclonal antibodies are recombinant. Owing to the recent rapid development of single-cell cloning technology, the process of antibody isolation has been dramatically shortened compared with the generation of a conventional monoclonal antibody secreted from a hybridoma resulting from the fusion of a mouse myeloma with B cells (Wan et al, 2020). However, since they are recombinant human antibodies produced in HEK293 cell lines derived from human embryonic kidney, they have a disadvantage compared to conventional hybridoma-produced antibodies in terms of their lot-to-lot quality control and manufacturing costs (Cohen, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection

Guo

Kawaguchi

Takeshita

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak in the winter of 2019. An extensive investigation of SARS-CoV-2 is critical for disease control. Various recombinant monoclonal antibodies of human origin that neutralize SARS-CoV-2 infection have been isolated from convalescent patients and will be applied as therapies and prophylaxis. However, the need for dedicated monoclonal antibodies in molecular pathology research is not fully addressed. Here, we produced mouse anti-SARS-CoV-2 spike monoclonal antibodies that exhibit not only robust performance in immunoassays including western blotting, ELISA, immunofluorescence, and immunoprecipitation, but also neutralizing activity against SARS-CoV-2 infection in vitro. Our monoclonal antibodies are of mouse origin, making them compatible with the experimental immunoassay setups commonly used in basic molecular biology research laboratories, and large-scale production and easy distribution are guaranteed by conventional mouse hybridoma technology.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection

Guo

Kawaguchi

Takeshita

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, the correlation between antibodies for different antigens (e.g., S and N proteins) may not be as initially conceived [35,38]. Human monoclonal antibodies that neutralize virus or pseudovirus especially recognized the RBD [39]. Collaborative groups have found a strong association between neutralizing antibodies and IgG antibodies to the RBD [36,40].…”

Section: Provisional Acceptance Of What Constitutes Immunitymentioning

confidence: 99%

A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19

Cimolai

2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Until either efficacious therapy or vaccination for COVID-19 is achieved, there will be a need to regain world economic stability while yet controlling the pandemic with current approaches. For those infected thus far, there is a prevailing perspective that devising recognition for protective immunity will progressively allow segments of society to return to some functionality more than is existing. At this time, the best correlates with protection from natural coronavirus infections are systemic neutralizing antibody and mucosal IgA. Serum neutralizing antibody more easily fulfills the latter requisite, but current live virus methods for neutralization prevent large-scale application. It is conceivable that the exposure of previously infected individuals can allow for the definition of protective thresholds of neutralizing antibody. Thereafter, many other antibody assays will be able to screen for surrogate protection after correlations with protective neutralizing antibody are made. Specificity of common antibody tests would benefit from confirmatory blocking systems or confirmatory immunoblotting fingerprints with well-defined antigen(s). The opportunity for the scientific community to make these assessments is evident in the current context of the COVID-19 epidemic given the large numbers of infected individuals worldwide. Such information will also be vital to guide vaccine development and/or immunotherapy.

show abstract

“…It has been shown that targeting S protein could neutralize known coronaviruses (e.g., SARS-CoV) and hinder their binding to the cells. In this regard, monoclonal antibodies (mAbs), single-chain variable fragments (scFvs), etc., have been utilized (6,(9)(10)(11). Several ongoing clinical trials are employing mAbs to neutralize the SARS-CoV-2 virus as a therapeutic regimen (12)(13)(14).…”

Section: Rationalementioning

confidence: 99%

An aptamer/ siRNA Chimera against The SARS-CoV-2: A Dual Therapeutic Strategy for The Virus Neutralizing and RNA Interfering

Khanali¹,

Azangou‐Khyavy²,

Asaadi³

et al. 2020

Preprint

View full text Add to dashboard Cite

During the ongoing COVID-19 pandemic, besides the vaccines, there is an urgent need for the development of effective therapeutics. Although significant efforts have been made to develop such therapies, there are currently no approved treatments for COVID-19. One of the potential therapeutic targets is the spike (S) protein of SARS-CoV-2, which mediates viral entry into host cells. It has been shown that targeting S protein could neutralize viruses and hinder their binding to the cells. Among known viral neutralizing agents, aptamers’ potential in neutralizing the SARS-Cov-2 virus has not yet been revealed. In addition, aptamers could also be used for targeted delivery of drugs and other genetic elements, such as siRNAs, to the cells. Small interfering RNAs (siRNAs) are reliable tools for gene knockdown via RNA degradation. siRNAs have been implemented previously against some viruses, including SARS-CoV, to target its genome. Recently, potential siRNA sequences and their targets in the SARS-CoV-2 genome have been reported, and the efficiency of siRNAs in inhibiting SARS-CoV-2 infection is being revealed. An alternative antiviral approach we propose here relies on an aptamer-siRNA-based system for the treatment of COVID-19. These aptamers could neutralize viruses by hindering their receptor-mediated endocytosis, and siRNAs could suppress the expression of viral genes and halt various aspects of its pathogenesis whenever the aptamers fail to neutralize the virus.

show abstract

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Cited by 153 publications

References 40 publications

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection

A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19

An aptamer/ siRNA Chimera against The SARS-CoV-2: A Dual Therapeutic Strategy for The Virus Neutralizing and RNA Interfering

Contact Info

Product

Resources

About